Trial Profile
The Renin-angiotensin System (RAS) in Barrett's Esophagus as Future Biomarkers for Dysplasia and Cancer? A Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary) ; Enalapril (Primary)
- Indications Barrett's oesophagus
- Focus Biomarker; Therapeutic Use
- 13 Sep 2016 New trial record